Topic: Opening Speech & China Biotech Innovation
Jeffrey Zhang Summit Chair, CHBD
Founder of PROMED; Former Vice President of Wuxi AppTec; Successively served as the head of new business development of Pfizer China, director of Johnson & Johnson China’s strategic market.
Topic: Cross-border Licensing Annual review
Sean Jiang CFA & CEO & Founder， YAFO Capital
20+ years Wall Street banking & investment experience with Roth Capital, Xiangcai Securities, etc. Former China GM of ISI Group (Evercore).
Topic: Japan Market Opportunity for Chinese Pharmas
Steve Engen Founder&President, Renexes LLC
20+ years of Japanese and American pharmaceutical industry experience, brought over dozen US pharmaceutical products to the Japanese market.
Topic: Bio-century Commercial section- the evolution of china pharma market
Tina Hou Global Partner, Mckinsey
Tina leads the new-product-launch work in McKinsey’s Pharmaceutical & Medical Products Practice in China and has extensive experience in launch excellence issues.
Topic: Global Transaction Experience – MNC Perspective
Cynthia Wang BD&Licensing Director, BioInnovation Asia, Les Laboratories SERVIER
Cynthia brings with her over 19 years of Healthcare/pharmaceutical industrial experience in China. Cynthia worked as Senior BD manager for Pfizer in Vaccine BD global M&A projects and managing full TAs of out-licensing BD activities
Topic: Swiss Biotech Innovation
Michael Altorfer CEO, Swiss Biotech Association
Dr. Michael Altorfer has more than 20 years of experience in the life science industry compromising both big pharma and smaller biotech organizations.
Topic: Booming biologics: business and investment impact on Med tech
Jimmy Jin Senior Director of BD Becton Dickinson & Company China
Jimmy Jin is leading business development for BD China. Prior to joining BD, he has worked as director of business development in Thermo Fisher China and a senior consultant in Bain & Company. He and his team have completed 20+ investment and collaboration projects in the sector of medical device, IVD, bio-tech, and analytical instrument.
Topic: From pipeline to topline, from China to the world.
Jiaxi Xu Chief Analyst, Industrial Securities
Dr. Xu was graduated from School of Life Sciences of Fudan University. He has rich research experience in pharma and insurance institutions. He led the team to win the No. 1 Best Analyst of New Wealth.
Topic: Cell therapy industry and outlook
Wenjun Sun SVP BD, JW Therapeutics
Wen-jun Sun has over 20 years of broad leadership experience at Merck ( MSD ) at the US global headquarter and MSD China, in R&D, Manufacturing, Finance, Business development and partnership management.
Topic: Innovative Opportunities and Challenges of Orphan Drugs in China
James Xue CEO & Founder, CANbridge
Dr. James Xue has spent 20+ years in pharmaceutical industry and is the founder, chairman & CEO of CANbridge Pharmaceuticals Inc., a bio-tech company focused on oncology and rare disease.
Alan Yan Co-founder, Chairman, CEO, Seprogenix
25 years+ of senior management experience in MNC；Served as the head of Sanofi Pasteur’s business operations in China, General Manager of Actelion China；Held senior management positions in Sandoz China and Merck Serono China；Management experience covers clinical development and regulatory matters, BD, marketing, business channel management and operations.
Topic: China Biotech, Lovely Bubble, Lovely Cream
Sam Ma Co-Founder, CHBD
Sam has over 25 years experience in China, EU, US, Japan and India Life science industry, including AIDEA Pharma Co. Ltd, Urihk Pharma, GSK China and Global and Eisai China.
Topic: Investment Strategy for the Pharmaceutical Industry: Innovation + Import Substitution Lead the Great Era of Pharmaceuticals
Xiangyang Du Chief Analyst, the pharmaceutical industry, South West Securities
Mr. Du was a doctoral candidate of the Chinese Academy of Sciences, received Master of Science degree from the Chinese Academy of Sciences. He has 6-year research experience in the pharmaceutical industry.
Topic: Pharma BD in China
Kui Wang Secretary General, CHBD
Mr. Wang has rich experience in pharma Business Development for more than 20 years with a record more than 50 M&A and licensing transactions. He worked in Saiya Consulting, Eisai Pharma, Leo Pharma, and Eddingpharm.
Topic: Intellectual Property Structures in Research Collaborations – Pitfalls and Solutions
Julian Thurston CEO&Founder , Theobald Associates
Julian Thurston has been “top ranked” for commercial lifesciences since the leading legal directories (such as Chambers, Legal 500 and PLC) began covering the sector, and in Chambers Global has been ranked one of the top 10 lawyers globally for commercial lifesciences for over 10 years.
Topic: Clinical Transformation of Cartilage 3D BioPrinting
Huimin Chen Founder&CEO, SinoBioPrint
Dr. Huimin Chen is the founder and CEO of Huaxia SinoBioPrint (Shanghai) Biotech Ltd. and Jiangyin StemEasy Biotech Ltd. He focuses on the research, development and clinical application of cartilage 3D bioprinted and stem cell regenerative medicine in orthopedics, sports medicine and plastic surgery.
Topic: Expanding the Frontiers of Neuroscience in China
June Yan CEO, Neurofront Therapeutics
20 years of experience working in the pharma industry in a variety of markets including the United States, China and Asia. June had multiple key leadership roles in pharma MNCs and biotech companies including 17 years in Eli Lilly, Celgene and BeiGene.
Disruptive approach to treat CNS diseases via the gut-brain axis: autism, a case study
David H Donabedian Co-founder & CEO, Axial Therapeutics
Since Axial’s launch in November 2016, David has raised significant capital from top-tier VCs, including Taiho, Seventure, Longwood and Domain Associates and assembled a renowned advisory and scientific board and established the company as a leader in the gut-brain-axis.